(Q41753267)

8 October 2017

0 references

Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis (English)

1 reference

8 October 2017

1 reference

Hye Duck Choi

1

1 reference

8 October 2017

Wan Gyoon Shin

series ordinal

2

1 reference

8 October 2017

Ju-Yeun Lee

series ordinal

3

1 reference

8 October 2017

Byoung Cheol Kang

series ordinal

4

1 reference

8 October 2017

language of work or name

1 reference

6 November 2014

1 reference

8 October 2017

published in

Vascular Pharmacology

1 reference

8 October 2017

volume

65-66

1 reference

8 October 2017

page(s)

23-30

1 reference

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Operating characteristics of a rank correlation test for publication bias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Expert commentary: the safety of fibrates in lipid-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

The Combination of Estimates from Different Experiments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Safety considerations with fibrate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Meta-analysis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Bias in meta-analysis detected by a simple, graphical test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Pharmacoepidemiology safety study of fibrate and statin concomitant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

A review of time courses and predictors of lipid changes with fenofibric acid-statin combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Effects of combination lipid therapy in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Effects of fibrates in kidney disease: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.11.002

10.1016/J.VPH.2014.11.002

7 January 2021

Identifiers

DOI

1 reference

8 October 2017

1 reference